Articles tagged with Mtor Pathway
Simultaneous inhibition of two signaling pathways, mTOR and MAPK, resulted in enhanced antitumor effects in mouse models of prostate and breast cancer. This combination therapy may improve the treatment of human cancers, particularly for patients with advanced, hormone-refractory prostate cancer.
Research led by Beth Israel Deaconess Medical Center identifies a previously unrecognized problem faced by mTORC1 inhibitors: activating the MAPK pathway, which encourages cancer cell survival. Scientists found that combining mTORC1 and MAPK inhibitors may offer a new treatment option for cancer patients.
Researchers found that simultaneously inhibiting the mTOR and MAPK signaling pathways enhanced antitumor effects in mouse models of prostate and breast cancer. This dual inhibition was particularly effective against aggressive forms of the disease, leading to a potential breakthrough for combination therapy.